Romosozumab

Romosozumab (brand name Evenity) is a monoclonal antibody used to treat osteoporosis in postmenopausal women. It works by increasing bone formation and decreasing bone resorption. This helps to reduce the risk of fractures in women with osteoporosis. Studies have shown that it can reduce the risk of vertebral fractures by up to 73% and nonvertebral fractures by up to 40%. It is administered as a subcutaneous injection once a month.

Romosozumab is a medication used to treat osteoporosis in specific adult populations at high risk of fractures. Here's a closer look at its function and applications:

What is Osteoporosis?

• Osteoporosis is a bone disease that weakens bones, making them more susceptible to fractures (breaks). It often develops with aging and is more common in women after menopause.

How Romosozumab Works:

• Romosozumab belongs to a class of drugs called sclerostin inhibitors. Sclerostin is a protein that suppresses bone formation.
• By inhibiting sclerostin, Romosozumab increases bone formation activity in the body, leading to denser and stronger bones.

Who can benefit from Romosozumab:

• Romosozumab is approved for use in adults with postmenopausal osteoporosis who have a high risk of fractures. This may include individuals with a history of fragility fractures or those who cannot tolerate other osteoporosis medications.

Dosage and Administration:

• Romosozumab is typically given as a monthly injection under the skin (subcutaneous injection) by a healthcare professional.
• It's usually followed by a different medication called alendronate (a bisphosphonate) for a certain duration to ensure long-term bone maintenance.

Important Considerations:

• Romosozumab is a prescription medication and should only be used under a doctor's supervision.
• Increased Risk of Fracture in the Jaw: A significant risk associated with Romosozumab is an increased chance of developing serious jawbone complications (osteonecrosis of the jaw) This risk is higher in patients who have undergone dental procedures recently, have poor dental hygiene, or are taking medications that affect jawbone health (such as corticosteroids).
• Other Potential Side Effects: Romosozumab can cause side effects like joint pain, headache, back pain, and dizziness.
• Not a First-Line Treatment: Due to the potential jawbone complications, Romosozumab is generally not recommended as the first-line therapy for osteoporosis. Doctors will consider other osteoporosis medications with a lower risk of side effects before using Romosozumab.